Supplementary Material
GROUP B
Supplementary Figure 1. Singleplex and Multiplex immunohistochemistry examples.Supplementary Table 1. Summary of patient disposition (Part 1a Group A) (Full Analysis Set)Supplementary Table 2. Summary of patient disposition (Part 1a Group B) (Full Analysis Set)Supplementary Table 3. Summary of patient disposition (Part 1b Expansion Group A-1/A-2) (Full Analysis Set)Summary of patient disposition (Part 1b Expansion Group B-1/B-2) (Full Analysis Set).Summary of patient disposition (Part 2) (Full Analysis Set)Summary of TEAEs by MedDRA preferred term [at least two patients (Part 1a Group A) or ≥10% of patients (Part 1a Group B, Part 1b, Part 2) in the safety population]Supplementary Table 7. Serious TEAE ≥5% of patients by MedDRA preferred term (safety population).Supplementary Table 8. Summary of steady state itacitinib pharmacokinetic parameters (cycle 2 day 1).Supplementary Table 9. Summary of steady state parsaclisib pharmacokinetic parameters (cycle 2 day 1).Supplementary Table 10. Plasma proteins differentially expressed between cycle 1 day 1 and cycle 2 day 1 with (A) itacitinib plus pembrolizumab (Part 1b Group A-1), or (B) parsaclisib plus pembrolizumab treatment (Part 1b Group B-1/B-2, and Part 2).